Related Experiment Video
Updated: Mar 20, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Targeted Therapy in Brain Metastases: Ready for Primetime?
Vyshak A Venur1, Manmeet S Ahluwalia1
1From the Division of Hematology and Oncology, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA; Burkhardt Brain Tumor and Neuro-Oncology Center, Department of Medicine, Neurologic Institute, Cleveland Clinic, Cleveland, OH; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Abstract:
Brain metastasis is a serious complication of cancer that causes significant morbidity for patients. Over the last decade, numerous new driver somatic mutations have been recognized and targeted therapies are changing the landscape of treatment in lung cancer, breast cancer, and melanoma, which are also the three most common cancers that result in brain metastases. The common actionable mutations include the EGFR mutation and anaplastic lymphoma kinase (ALK) translocations in non-small cell lung cancer, the HER2 mutation in breast cancer, and the BRAF mutation in melanoma. However, most of the early trials with targeted agents excluded patients with brain metastases. With a better understanding of the biology, several recent trials of targeted therapy that focus on brain metastases have been reported and others are ongoing. Novel agents with better penetration across the blood-brain barrier are currently being investigated for patients with brain metastases. In this review, we discuss the current state of use and future directions of targeted therapies in brain metastases.
Insights
Targeted therapies are revolutionizing cancer treatment, especially for brain metastases from lung cancer, breast cancer, and melanoma. Research is advancing to improve drug delivery across the blood-brain barrier for better patient outcomes.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Brain metastasis is a significant cause of cancer-related morbidity.
- Targeted therapies have transformed treatment for lung cancer, breast cancer, and melanoma.
- Historically, patients with brain metastases were often excluded from clinical trials.
Purpose of the Study:
- To review the current applications of targeted therapies in brain metastases.
- To discuss the future directions for treating brain metastases with targeted agents.
- To highlight novel agents with improved blood-brain barrier penetration.
Main Methods:
- Review of recent clinical trials and ongoing research in targeted therapy for brain metastases.
- Analysis of common actionable mutations (EGFR, ALK, HER2, BRAF) in relevant cancers.
- Discussion of pharmacokinetic challenges and solutions for blood-brain barrier penetration.
Main Results:
- Several targeted therapy trials specifically for brain metastases have been reported.
- Ongoing trials are investigating novel agents with enhanced blood-brain barrier penetration.
- Understanding cancer biology is crucial for developing effective brain metastasis treatments.
Conclusions:
- Targeted therapies show promise for managing brain metastases.
- Further research is needed to optimize drug delivery and efficacy.
- Future strategies will focus on overcoming the blood-brain barrier to improve patient survival and quality of life.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...